Heart Disease News and Research

Latest Heart Disease News and Research

Transgenomic signs definitive agreement to acquire diagnostic business of Clinical Data

Transgenomic, Inc. announced today the signing of a definitive agreement for Transgenomic to acquire the diagnostic business of Clinical Data, Inc. This acquisition includes a suite of proprietary genetic commercial tests, certain proprietary biomarker assays, and the CLIA-certified laboratory operations of Clinical Data for a purchase price of approximately $15.4 million, primarily in cash and notes.

29 Nov 2010

Ageing reversed in mice: Study

A scientific team at Harvard-affiliated medical centers genetically manipulated mice to age faster. Then they used gene therapy to lengthen telomeres. Telomeres are compounds found at the ends of strands of DNA that are related to age. This lengthening of telomeres reversed age-related problems such as decreased brain function and infertility.

29 Nov 2010

MEDRAD launches VirtualCARE solution for Intego PET Infusion System

MEDRAD, Inc. a business of Bayer HealthCare, today announces the U.S. launch of VirtualCARE®, for the MEDRAD Intego™ PET Infusion System. VirtualCARE is a technology platform that allows MEDRAD to remotely support maintenance and system updates securely over the internet.

29 Nov 2010

DK Sinopharma third quarter sales increase 66% to $7,290,685

DK Sinopharma, Inc., announced its third quarter 2010 financial results. The Company's quarterly report on Form 10-Q was filed with the U.S. Securities & Exchange Commission on November 22, 2010.

29 Nov 2010

FDA approves Merit's phase 3 clinical trial protocol to treat primary liver cancer with QuadraSphere Microspheres

The Food and Drug Administration (FDA) has approved Merit Medical Systems, Inc.'s phase 3 clinical trial protocol to treat primary liver cancer with QuadraSphere™ Microspheres (hqTACE) for delivery of doxorubicin. The clinical trial will involve U.S. and international interventional radiologists who treat patients with localized, unresectable hepatocellular carcinoma (HCC), the most common form of liver cancer.

29 Nov 2010

ZONARE announces 11th software release for z.one ultrasound platform at RSNA 2010

ZONARE Medical Systems, Inc., a developer of high-end ultrasound solutions, today announced a new software release for its z.one ultrasound platform here at the 96th Annual Meeting of the Radiological Society of North America (RSNA), Nov. 28 – Dec. 3, 2010. Designed to continually improve image quality and system performance, the 11th software release in six years also includes new advanced software applications and transducers which further expands the clinical utility of the z.one system in radiology, obstetric and vascular imaging.

29 Nov 2010

Ziosoft announces launch of PhyZiodynamic solutions at RSNA 2010

Ziosoft, Inc., a leader in functional visualization and analytics, will launch its PhyZiodynamic solutions at the Radiology Society of North America (RSNA) being held November 28 – December 3, 2010 in Chicago. PhyZiodynamic solutions represent a generational leap in advanced visualization.

29 Nov 2010

Micell initiates enrollment in DESSOLVE I clinical trial of MiStent DES

Micell Technologies,™ Inc. today announced it has enrolled at Mercy Hospital in Auckland, New Zealand, the first patient in DESSOLVE I (DES with Sirolimus and a bioabsorbable pOLymer for the treatment of patients with de noVo lEsions in the native coronary arteries), a first-in-human clinical trial of the company's investigational MiStent™ Drug Eluting Coronary Stent System (MiStent DES).

29 Nov 2010

Weight Watchers introduces PointsPlus weight loss program in the U.S.

The new era of Weight Watchers is here. Today Weight Watchers, the world-renowned leader in weight management, has announced it is introducing in the United States a successor to its popular POINTS weight loss system–the new PointsPlus program.

29 Nov 2010

Amarin reports top-line results from AMR101 Phase 3 trial for treatment of high triglycerides

Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported positive, statistically significant top-line results from the MARINE study, its first Phase 3 clinical trial of lead drug candidate AMR101.

29 Nov 2010

Toshiba announces multi-center trial to evaluate Time-SLIP Renal MR Angiography

Non-contrast MR angiography provides clear, high-quality images and can be used as an effective tool for diagnosing renal artery stenosis. To illustrate non-contrast MRA's ability as a diagnostic tool for renal artery stenosis, Toshiba has announced a multi-center trial to establish the clinical value of non-contrast Renal MRA using Time-SLIP.

29 Nov 2010

Affymax, Takeda to regulate peginesatide drug for treating anemia in CRF patients

Affymax, Inc. and Takeda Pharmaceutical Company Limited , today announced that following pre-New Drug Application (NDA) discussions with the U.S. Food and Drug Administration (FDA), the companies will move forward with their regulatory strategy for the investigational drug, peginesatide, for the treatment of anemia in chronic renal failure (CRF) patients on dialysis in the United States.

29 Nov 2010

Researchers identify effects of endurance running

Using a mobile MRI unit, researchers followed runners for two months along a 4,500-kilometer course to study how their bodies responded to the high-stress conditions of an ultra-long-distance race, according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).

29 Nov 2010

Walking may slow cognitive decline in adults with MCI, Alzheimer's disease

Walking may slow cognitive decline in adults with mild cognitive impairment (MCI) and Alzheimer's disease, as well as in healthy adults, according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).

29 Nov 2010

Jefferson Hospital offers shortest wait times for patients seeking kidney transplant: SRTR

A recent listing of Philadelphia adult kidney transplant programs by The Scientific Registry of Transplant Recipients (SRTR) has listed the transplant program at Thomas Jefferson University Hospital as having the shortest wait times for patients seeking a transplant among programs that have a three-year survival rate of greater than 90 percent.

29 Nov 2010

New strategy to prevent memory deficits in mouse model with AD

Scientists at the Gladstone Institute of Neurological Disease (GIND) in San Francisco have discovered a new strategy to prevent memory deficits in a mouse model of Alzheimer's disease (AD).

28 Nov 2010

Toshiba to highlight dose reduction technologies at RSNA annual meeting

Reducing radiation dose is a high priority for medical imaging manufacturers and healthcare facilities. Expanding its dedication to reducing CT radiation dose while maintaining diagnostic confidence, Toshiba America Medical Systems, Inc. is expanding its suite of low dose CT technologies. Toshiba will showcase dose reduction technologies, such as Target CTA and Adaptive Iterative Dose Reduction (AIDR), at this year's Radiological Society of North America (RSNA) annual meeting, held in Chicago, Nov. 28 - Dec. 3, 2010

28 Nov 2010

ESF report: Reduced male fertility may contribute to low birth rates

Reduced male fertility may be making it even harder for couples to conceive and be contributing to low birth rates in many countries, reveals a new European Science Foundation (ESF) report launching today at the IPSEN meeting in Paris.

28 Nov 2010

Alpha carotene increase life span: Study

A new study shows that and antioxidant alpha carotene found in vegetables can reduce the risk of premature death and allow for a longer, healthier lifespan. The study led by Dr. Chaoyang Li from the U.S. Centers for Disease Control and Prevention (CDC) involved nearly 15,000 adults who were all age 20 and older. It spanned over 1988 to 1994, with patients being followed-up with in the year 2006. The plan was to look at the effect of an antioxidants found in vegetables on the health of people.

28 Nov 2010

Segasist Technologies receives HTX funding for clinical validation of prostate MRI software

Segasist Technologies, a Canadian software company developing contouring productivity tools for medical imaging, has today announced the receipt of funding from The Health Technology Exchange (HTX) towards support of clinical validation of its software, to be conducted at the Lawson Health Research Institute and London Health Sciences Centre (London, Ontario). Experts from Sunnybrook Research Institute and Sunnybrook Health Sciences Centre will also participate in the validation process by providing input in the form of gold standard contours.

26 Nov 2010